Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Amgen’s Lumakras Obtains Early FDA Approval for KRAS-Mutated NSCLC

drugsJune 01, 2021

Tag: NSCLC , Lumakras , KRAS

PharmaSources Customer Service